Author:
Ren S.,Jin Y.,Huang Y.,Ma L.,Liu Y.,Meng C.,Guan S.,Xie L.,Chen X.
Funder
The Twelfth Five-Year Major Science and Technology projects
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference21 articles.
1. Chen X, Shang J, Yang R, Xie Q, Gao Z, Xu X et al (2015) High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na(i)ve patients: a multicenter randomized study. Zhonghua Gan Zang Bing Za Zhi (Engl) 23(6):412–417
2. Pawlotsky JM (2014) New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146:1176–1192
3. Kumthip K, Maneekarn N (2015) The role of HCV proteins on treatment outcomes. Virol J 12:217
4. Rosenquist Å, Samuelsson B, Johansson PO, Cummings MD, Lenz O, Raboisson P et al (2014) Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J Med Chem 57:1673–1693
5. Marcellin P, Reau N, Ferenci P, Hadziyannis S, Messinger D, Tatsch F et al (2012) Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol 56(6):1276–1282